- Home
- LSBK vs PRLD Comparison
LSBK vs PRLD Comparison
Compare LSBK & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- PRLD
- Stock Information
- Founded
- LSBK 1891
- PRLD 2016
- Country
- LSBK United States
- PRLD United States
- Employees
- LSBK N/A
- PRLD N/A
- Industry
- LSBK Savings Institutions
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- LSBK Finance
- PRLD Health Care
- Exchange
- LSBK Nasdaq
- PRLD Nasdaq
- Market Cap
- LSBK 76.9M
- PRLD 63.3M
- IPO Year
- LSBK 2006
- PRLD 2020
- Fundamental
- Price
- LSBK $13.51
- PRLD $1.04
- Analyst Decision
- LSBK
- PRLD Buy
- Analyst Count
- LSBK 0
- PRLD 3
- Target Price
- LSBK N/A
- PRLD $5.33
- AVG Volume (30 Days)
- LSBK 1.2K
- PRLD 408.0K
- Earning Date
- LSBK 10-23-2024
- PRLD 11-06-2024
- Dividend Yield
- LSBK 5.33%
- PRLD N/A
- EPS Growth
- LSBK N/A
- PRLD N/A
- EPS
- LSBK 0.75
- PRLD N/A
- Revenue
- LSBK $25,338,000.00
- PRLD $3,000,000.00
- Revenue This Year
- LSBK N/A
- PRLD N/A
- Revenue Next Year
- LSBK N/A
- PRLD N/A
- P/E Ratio
- LSBK $18.10
- PRLD N/A
- Revenue Growth
- LSBK N/A
- PRLD N/A
- 52 Week Low
- LSBK $10.12
- PRLD $1.00
- 52 Week High
- LSBK $14.21
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- LSBK 49.26
- PRLD 21.69
- Support Level
- LSBK $13.38
- PRLD $1.14
- Resistance Level
- LSBK $13.90
- PRLD $1.36
- Average True Range (ATR)
- LSBK 0.15
- PRLD 0.11
- MACD
- LSBK -0.02
- PRLD 0.03
- Stochastic Oscillator
- LSBK 37.14
- PRLD 7.53
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.